Fabupharm products announces expansion
Fabupharm Products, a 100% Namibian pharmaceutical manufacturer with an official manufacturing GMP (Good Manufacturing Practice) Licence from the Namibian Medicines Regulatory Council (NMRC), recently announced plans to expand.
“There are opportunities to export our products to surrounding countries and to the growing local market,” says Carl Brinkmann, Sales Director at Fabupharm Products.
“We are also adding value to Namibia by procuring materials locally such as Devil’s Claw, Hoodia and Mancetti Oil. Our decision to expand is based on the fact that health care is a growing market.”
The expansion entails bringing new products to the market, which requires constructing additional production rooms. The manufacturer also plans to invest in new equipment and upgrade or replace old equipment. They will focus on replacing the High Performance Liquid Chromatograph, which is essential laboratory equipment.
“In the previous financial year we invested N$3.4 million in clean room technology; internal and external production division; the air handling system; a sachet filling and blending machine and a capsule polisher,” says Brinkmann. According to him these investments are necessary in order to remain GMP compliant.
In the last financial year Fabupharm’s revenue grew by 57%. Due to the investments in the manufacturing plant the number of employees grew from 35 to 65. Moreover, Fabupharm launched four new products last year.
“We expect a further 35% growth in jobs following our expansion plans. We will also launch a number of new products in the coming year,” says Fanie Badenhorst, Managing of Fabupharm. The company expects to double their capacity.
New products which were recently launched are: Suplimax Charcoal Capsules; Suplimax Joint Pain Relief; Suplimax Fibrelle Capsules; the Ideal for Baby range; as well as the Fabupharm Plus cream range. In addition, Fabupharm expects to launch two more products soon namely Suplimax Q-Calmag-D and Suplimax Diabetic Care.
Fabupharm Products is a member of the Namibia Manufacturers’ Association (NMA) and participated in the recently held Made in Namibia Expo.
“There are opportunities to export our products to surrounding countries and to the growing local market,” says Carl Brinkmann, Sales Director at Fabupharm Products.
“We are also adding value to Namibia by procuring materials locally such as Devil’s Claw, Hoodia and Mancetti Oil. Our decision to expand is based on the fact that health care is a growing market.”
The expansion entails bringing new products to the market, which requires constructing additional production rooms. The manufacturer also plans to invest in new equipment and upgrade or replace old equipment. They will focus on replacing the High Performance Liquid Chromatograph, which is essential laboratory equipment.
“In the previous financial year we invested N$3.4 million in clean room technology; internal and external production division; the air handling system; a sachet filling and blending machine and a capsule polisher,” says Brinkmann. According to him these investments are necessary in order to remain GMP compliant.
In the last financial year Fabupharm’s revenue grew by 57%. Due to the investments in the manufacturing plant the number of employees grew from 35 to 65. Moreover, Fabupharm launched four new products last year.
“We expect a further 35% growth in jobs following our expansion plans. We will also launch a number of new products in the coming year,” says Fanie Badenhorst, Managing of Fabupharm. The company expects to double their capacity.
New products which were recently launched are: Suplimax Charcoal Capsules; Suplimax Joint Pain Relief; Suplimax Fibrelle Capsules; the Ideal for Baby range; as well as the Fabupharm Plus cream range. In addition, Fabupharm expects to launch two more products soon namely Suplimax Q-Calmag-D and Suplimax Diabetic Care.
Fabupharm Products is a member of the Namibia Manufacturers’ Association (NMA) and participated in the recently held Made in Namibia Expo.
Kommentaar
Republikein
Geen kommentaar is op hierdie artikel gelaat nie